Moderna shares double after Phase 3 cancer vaccine breakthrough

Moderna's stock surged 131% after the company announced a Phase 3 clinical trial win for its cancer vaccine, beating the current standard of care. Short sellers lost an estimated $4.8 billion as the biotech's shares doubled. The breakthrough marks a significant milestone in Moderna's push beyond its mRNA COVID-19 vaccine.